Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-treatment outcomes after TRIUMPH study in HER2-positive metastatic colorectal cancer
jRCT1030220064Active, not recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab and pertuzumab in colorectal cancer (CRC), sponsored by National Cancer Center Hospital East. Primary endpoint: Overall survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
trastuzumabpertuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1030220064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030220064.